Blase Polite to Cost-Benefit Analysis
This is a "connection" page, showing publications Blase Polite has written about Cost-Benefit Analysis.
Connection Strength
0.174
-
A Pathway Through the Bundle Jungle. J Oncol Pract. 2016 06; 12(6):504-9.
Score: 0.100
-
Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncol. 2019 02 01; 5(2):236-242.
Score: 0.030
-
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016 08 20; 34(24):2925-34.
Score: 0.025
-
Value-based insurance design in oncology. Lancet Oncol. 2011 Apr; 12(4):321-3.
Score: 0.018